CN115776885A - 用于治疗阿尔茨海默病和帕金森病的组合物和方法 - Google Patents

用于治疗阿尔茨海默病和帕金森病的组合物和方法 Download PDF

Info

Publication number
CN115776885A
CN115776885A CN202080102343.2A CN202080102343A CN115776885A CN 115776885 A CN115776885 A CN 115776885A CN 202080102343 A CN202080102343 A CN 202080102343A CN 115776885 A CN115776885 A CN 115776885A
Authority
CN
China
Prior art keywords
azelastine
pharmaceutical composition
disease
present
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080102343.2A
Other languages
English (en)
Chinese (zh)
Inventor
王建民
崔歌平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Pharmaceutical Research Technology Co ltd
Original Assignee
La Pharmaceutical Research Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Pharmaceutical Research Technology Co ltd filed Critical La Pharmaceutical Research Technology Co ltd
Publication of CN115776885A publication Critical patent/CN115776885A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080102343.2A 2020-06-26 2020-06-26 用于治疗阿尔茨海默病和帕金森病的组合物和方法 Pending CN115776885A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/039916 WO2021262196A1 (en) 2020-06-26 2020-06-26 Compositions and methods for treating alzheimer's disease and parkinson's disease

Publications (1)

Publication Number Publication Date
CN115776885A true CN115776885A (zh) 2023-03-10

Family

ID=79281652

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080102343.2A Pending CN115776885A (zh) 2020-06-26 2020-06-26 用于治疗阿尔茨海默病和帕金森病的组合物和方法

Country Status (5)

Country Link
EP (1) EP4171539A4 (de)
JP (1) JP2023539405A (de)
CN (1) CN115776885A (de)
CA (1) CA3183560A1 (de)
WO (1) WO2021262196A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
CN101134048A (zh) * 2007-05-31 2008-03-05 复旦大学附属中山医院 一种预防和治疗阿尔茨海默病与衰老的药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP5607291B2 (ja) * 2004-11-24 2014-10-15 メダ ファーマシューティカルズ インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
WO2007030108A1 (en) * 2005-09-07 2007-03-15 Bebaas, Inc. Vitamin b-12 compositions
WO2007061454A1 (en) * 2005-11-22 2007-05-31 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
JP2010260808A (ja) * 2009-05-01 2010-11-18 Ikeda Mohando:Kk 肌状態改善用経口医薬組成物
US20190030061A1 (en) * 2016-03-01 2019-01-31 Nova Southeastern University Cobalamin compositions and use thereof for improving cognitive function
US10639314B1 (en) * 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
CN101134048A (zh) * 2007-05-31 2008-03-05 复旦大学附属中山医院 一种预防和治疗阿尔茨海默病与衰老的药物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DURAISAMY KEMPURAJ 等: "Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells", INT ARCH ALLERGY IMMUNOL., vol. 132, no. 3, 31 December 2003 (2003-12-31), pages 231 *
QAMRE ALAM等: "Inflammatory Process in Alzheimer\'s and Parkinson\'s Diseases: Central Role of Cytokines", CURR PHARM DES, vol. 22, no. 5, 31 December 2016 (2016-12-31), pages 541 *
刘建军等: "阿尔茨海默症的药物治疗", 安徽医药, vol. 4, no. 2, 31 December 2000 (2000-12-31), pages 17 - 18 *

Also Published As

Publication number Publication date
EP4171539A1 (de) 2023-05-03
EP4171539A4 (de) 2024-01-17
JP2023539405A (ja) 2023-09-14
WO2021262196A1 (en) 2021-12-30
CA3183560A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
US11318144B2 (en) Compositions and methods for treating Alzheimer's disease and Parkinson's disease
CN115776885A (zh) 用于治疗阿尔茨海默病和帕金森病的组合物和方法
US11116773B2 (en) Method of treating dementia
US10898493B2 (en) Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US12138269B2 (en) Method of treating dementia
US11938139B2 (en) Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
KR101581611B1 (ko) 정신, 행동, 인지 장애의 예방 및 치료용 약학적 조성물
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
US20210069209A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
WO2021242297A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
US11744833B2 (en) Pharmaceutical compositions and methods for treatment of insomnia
EP1513533A2 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
EP4478887A1 (de) Neue pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit
WO2011110608A1 (en) Treatment of dementia of alzheimer's type with masitinib
KR20210133495A (ko) 옥수수불검화 정량 추출물 및 후박 추출물을 유효성분으로 포함하며 iLet(innovative Low excipient tablet) 기술을 이용한 정제사이즈 축소를 통해 복용 편의성이 향상된 치주질환 예방 또는 치료용 약학적 조성물
HK1100840A (en) Compositions and methods to treat recurrent medical conditions
DE10310396A1 (de) Verwendung von Antihistaminika sowie pharmazeutische Wirkstoffkombination

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination